Finigan Paul M 4
4 · CURAGEN CORP · Filed Oct 5, 2009
Insider Transaction Report
Form 4
CURAGEN CORPCRGN
Finigan Paul M
Former EVP & General Counsel
Transactions
- Disposition to Issuer
Common Stock
2009-10-01−75,000→ 0 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-10-01−204,800→ 0 totalExercise: $0.68Exp: 2010-10-01→ Common Stock (204,800 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2009-10-01−180,626→ 0 totalExercise: $0.69Exp: 2010-10-01→ Common Stock (180,626 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to merger agreement between issuer and Celldex Therapeutics, Inc. in exchange for 20,542 shares of Celldex Therapeutics, Inc. common stock having a market value of $19.82 per share on the effective date of the merger, October 1, 2009.
- [F2]This option vested 25% on January 24, 2009 and 6.25% quarterly thereafter until the effective date of the merger at which time the option was accelerated and assumed by Celldex Therapeutics, Inc. and replaced with an option to purchase 49,473 shares of Celldex Therapeutics, Inc. common stock for $2.52 per share.
- [F3]This option, which accelerated on October 1, 2009, was assumed by Celldex Therapeutics, Inc. in the merger and replaced with an option to purchase 56,094 shares of Celldex Therapeutics, Inc. common stock for $2.48 per share.